Lupin’s
biological pursuit
Dr
Kamal Sharma, managing director, Lupin, Mumbai.
Having consolidated itself in the generics space, Lupin Pharma has now
marked biologics as a top priority within the radar of its overall
expansion plans Lupin Pharma has been very aggressive in the last few
months announcing a spate of overseas acquisitions, capacity expansion
plans and now its foray into biological venture. A statement made by
company Chairman, Dr DB Gupta earlier last year categorically
mentioned, “We have planned to make substantial investments
in this area as we believe biotechnology is the frontier area of
technology. Over 40 percent of all future discoveries in
pharmaceuticals are expected from biologicals. I believe concrete
outcome of our research work done should start getting market
recognition soon. Our innovative research is focused largely on four
areas--New Chemical Entity Research, New Biological Entity Research,
Advanced Drug Delivery Systems Research, and Innovative Generics
Research. In all these areas a sound base has been created including
initiation in the Biotech area.” Overall
too, it has been all sunshine for Lupin Pharma which posted a
consolidated net profit for the year ended March 31, 2008, of
Rs 408.25 crore up by 32 per cent. Total income increased
from Rs 2,212.76 crore for the year ended March 31, 2007 to Rs 2,912.82
crore for the year ended March 31, 2008. Chunk of the revenue share
came from international operations.
The company’s biotech sojourn began two years back
when it set up an R&D unit dedicated just to
specialized research and development of a basket of proteins.
From then on the company has moved on at a breakneck speed.
Dr Kamal Sharma, managing director, Lupin said, “We initiated
our biological venture two years ago and obviously we began
with plans of going into the R&D space. Within this period, we
have developed some proteins and some monoclonal antibodies too, some
of them are in advanced stages of development and some of them are in
the intermediary stages of development”
New manufacturing unit
and investments
Moving ahead, the company now does not want to leave any stone unturned
in its biological venture. It has already made some significant
investments in establishing a research unit for biosimilars namely the
Lupin Biosimilars Research organization and new biological entities.
This is not all. As a stepping stone to its biological dreams, Lupin is
now setting up its own manufacturing unit in Pune which is likely to be
commissioned in the coming months. While the Lupin
Biosimilars Research organization in Pune is fully operational, the
manufacturing and technical arms are being currently ramped up. Lupin
has developed several biosimilars as well as delivery platforms for
proteins and completed pilot work on two monoclonal antibodies of
global potential.
“We set up a manufacturing unit which will be commissioned in
the course of the next three months in Pune. Here, we are
going to take up the clinical manufacturing of the proteins we have
developed already and then put them for regulatory approval.
It is a CGMP facility,” added Dr Sharma.
When the manufacturing facility is ready, it would offer facilities for
any clinical production or contract manufacturing services which
overseas companies may require. Thus the setting up of its
technological and manufacturing arm is not just an extension but a
catalyst to further Lupin’s biologics strategy both in India
and overseas markets.
Disease segment of prime importance for Lupin in biologicals will be
cancer, cardiovascular and rheumatoid arthritis. Lupin aims to reach
all key global markets including the US, Europe, India, Brazil, Mexico,
Turkey, Saudi Arabia, Argentina and Russia.
Investments
As far as investments go, funds and finances could go up to the tune of
Rs 250 crore for Lupin’s entire biological
initiative with the entire amount being raised from internal accruals
alone. However it is here that Lupin wants to take it up one at a time.
“Obviously in trying to respect the economics of the
business, we have kept it in a manner that we do not invest
too much money upfront and invest as and when required. We have not
allocated any separate budget but whatever initiative is
taken, we look at it as a return on investment ranging
between 25-30 percent. Unless that return on investment is
insured we do not take a step ,” confirmed Dr Sharma
Dr Sharma, who is spearheading the company’s
biological initiatives has a different mantra to keep the business up
and running . He quipped, “What drives us is output not
input. I am an advocate of concentrating more on output than input. It
would make economic sense to have a situation where 50 people
can create a Rs 500 crore business; a four acre plot generating Rs 400
crore business rather than making huge investment and getting nothing
out of it.” The same goes with its manpower investments too.
In the span of two years, the company ramped up its workforce to over
35 and now with the setting up of its manufacturing unit and
technological arm, it intends to beef up its total workforce to 100 and
above which will be divided into research, manufacturing and Q/A. Lupin
is looking at focusing on the right number of high quality people which
will be determined more by the needs of the
business.
Strategy
Venturing into the manufacturing is in line with the overall
blueprint of Lupin’s broad strategy. The
company’s business model consists of four
components which is in-licensing products (wherein the company has
already in-licensed products for biologics in the market); having its
own manufacturing plant; scouting partners for taking an early stage
product into clinical development including co development in India;
and last, forging marketing alliances. “Our
technology and manufacturing strategies are going to be different as
this is altogether a different science. But the new strategy for
technology and manufacturing will dovetail into our main line
strategy for putting the product into the market. So we are
starting with a new technology platform which is biologicals, starting
with biosimilars moving into New Biological Entities for which we will
enter into codevelopment and in licensing for early
deals,” added Dr Sharma.
Looking at the macro level, getting into an acquisition or an
alliance with a “strategic fit” has always been
Lupin’s core strategy and it intends to emulate the same in
its biotech model as well. “We do not acquire for the sake of
becoming big but we are acquiring for the sake of adding strength to
our base model. This can be done only by two methods. One is to acquire
in the market you want to enter which is difficult
to enter in an organic way or you acquire a
technology platform to add to your business. It is this that
will be applied to our biopharmaceuticals model as well,” Dr
Sharma said.
Lupin’s manufactured products is estimated to be
out in the market by the end of 2010 It is a prerequisite in
the company’s agenda that the products
are first launched in India and then in overseas markets. In
the process, the company will start developing partnerships.
Partnerships will go concurrent.
Looking into the future
The share of biologics in Lupin’s total revenues would be
minuscule in the next one year, despite in-licensing deals and
marketing alliances. The company is looking at a business turnover of
Rs 100 crore from this business in the initial years and gradually
increase the share of revenues from the biologics business to 10
percent over the next seven-eight year’s time.
On a final note, Dr Sharma added optimistically, “I can
confidently say, that we have gone into the biologics space at the
right time. The regulatory pathway for biosimilars is just up in the US
. It will take another 3-4 years before it gets settled into a well
defined pathway. By then our technology and manufacturing would have
graduated to a higher level by then which makes work easier for us and
help us ink further alliances. I am pretty much excited about
that.”
Nayantara Som